Keyphrases
Interleukin-13 (IL-13)
100%
Anti-glioma
100%
Chimeric Antigen Receptor T Cells (CAR-T)
100%
Receptor Subunits
100%
Interleukin-15 (IL-15)
100%
Transgenic Expression
100%
Loss-variants
100%
Antigen Loss
100%
T Cells
53%
Glioblastoma
30%
Genetic Modification
15%
Glioma
15%
Proliferative Activity
15%
T Cell Persistence
15%
Antitumor Activity
7%
Improved Outcomes
7%
Glioma Cells
7%
Cell Viability
7%
Survival Benefit
7%
Recurring
7%
Primary Brain Tumor
7%
Clinical Testing
7%
Cytokine Production
7%
Conventional Therapy
7%
Tumor Antigen
7%
Human Epidermal Growth Factor Receptor 2 (HER2)
7%
Glioma Model
7%
T Cell Proliferation
7%
Multiple Tumors
7%
Multiple Antigens
7%
Vector Encoding
7%
Retroviral Vector
7%
T Cell Effector Function
7%
Repeated Stimulations
7%
Cell Injection
7%
EGFR Variant III
7%
Immunology and Microbiology
Transgenics
100%
Chimeric Antigen Receptor T-Cell
100%
T Cell
100%
Chimeric Antigen Receptor
62%
Cytokine
25%
Immunotherapy
25%
T Cell Proliferation
12%
Glioma Cell
12%
Cell Viability
12%
Cytokine Production
12%
Antineoplastic Activity
12%
Retrovirus Vector
12%
Tumor Antigen
12%
Immunology
12%
Medicine and Dentistry
Receptor Subunit
100%
Chimeric Antigen Receptor T-Cell
100%
T Cell
61%
Chimeric Antigen Receptor
38%
Glioblastoma
30%
Ganglioglioma
23%
Cytokine
15%
Immunotherapy
15%
Recurrent Disease
7%
Intracranial Tumor
7%
Epidermal Growth Factor Receptor
7%
Malignant Neoplasm
7%
Cytokine Production
7%
Antineoplastic Activity
7%
Tumor Antigen
7%
Cell Viability
7%
Glioma Cell
7%
Proteus Syndrome
7%
Retrovirus Vector
7%
T Cell Proliferation
7%